Using high-intensity ultrasound to treat heart obstruction in hypertrophic cardiomyopathy
High-Intensity Ultrasound Ablation for Septal Reduction Therapy of Hypertrophic Cardiomyopathy
This study is testing a new, less invasive ultrasound treatment for people with obstructive hypertrophic cardiomyopathy (HCM) to help reduce heart muscle thickness and improve heart function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11038040 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for obstructive hypertrophic cardiomyopathy (HCM), a condition that causes significant heart-related symptoms due to blockage in the heart's outflow tract. The approach utilizes high-intensity ultrasound to reduce the thickness of the heart muscle in a less invasive manner compared to traditional methods. By targeting specific areas of the heart while minimizing damage to surrounding tissues, this technique aims to improve patient outcomes and reduce complications. The research will optimize the ultrasound technique and prepare for initial human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with obstructive hypertrophic cardiomyopathy who experience significant symptoms due to left ventricular outflow tract obstruction.
Not a fit: Patients with non-obstructive forms of hypertrophic cardiomyopathy or those who are not experiencing severe symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients suffering from obstructive hypertrophic cardiomyopathy.
How similar studies have performed: Previous research has shown promise in using ultrasound techniques for cardiac treatments, suggesting potential success for this novel approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Nazer, Babak — University of Washington
- Study coordinator: Nazer, Babak
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.